DGX vs TMO
DGX: A leading national provider of diagnostic testing and medical insights, delivering clinical laboratory services through an extensive network of patient centers and hospitals. TMO: Thermo Fisher Scientific is a global leader in serving science, providing an extensive portfolio of analytical instruments, laboratory equipment, and mission-critical consumables for the life sciences and healthcare industries.
Side-by-side fundamentals
| Metric | DGX | TMO | Edge |
|---|---|---|---|
| Price as of 2026-07-23 close | $227.90 | $572.32 | |
| Market cap as of 2026-07-24 | $24.9B | $214.1B | |
| P/E as of 2026-07-24 | 24.34 | 31.28 | DGX lower |
| PEG as of 2026-07-24 | 2.41 | 2.89 | DGX lower |
| Net margin as of 2026-07-24 | +9.1% | +15.2% | TMO higher |
| Gross margin as of 2026-07-24 | +33.3% | +40.9% | TMO higher |
| Operating margin as of 2026-07-24 | +14.3% | +17.5% | TMO higher |
| ROE as of 2026-07-24 | +14.1% | +13.2% | DGX higher |
| ROA as of 2026-07-24 | +6.3% | +6.4% | TMO higher |
| Debt / equity as of 2026-07-24 | 0.77 | 0.83 | DGX lower |
| Revenue growth (YoY) as of 2026-07-24 | +11.0% | +5.4% | DGX higher |
| Revenue CAGR (3y) SEC XBRL | +3.7% | -0.3% | DGX higher |
| Dividend yield as of 2026-07-24 | +1.6% | +0.4% | DGX higher |
| Dividend streak (yrs) SEC XBRL | 5 | 5 | Tie |
| Beta as of 2026-07-24 | 0.54 | 0.84 | |
| 1-year return as of 2026-07-23 close | +33.7% | +22.6% | DGX higher |
Fundamentals: Finnhub, as of 2026-07-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-23.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.